Navigation Links
Role seen for cannabis in helping to alleviate allergic skin disease
Date:8/16/2007

dy to a long list of neurological diseases, such as multiple sclerosis, Alzheimer's and Parkinson's.

In the article in Science, the researchers detail how the endocannabinoid system serves as a major regulator of cutaneous (skin) contact hypersensitivity (CHS) in a mouse model. In this model, they showed, for example, that mice lacking cannabinoid receptors display exacerbated inflammatory skin responses to an allergen.

Because the data indicate that enhanced activation of the endocannabinoid system may function to dampen the CHS response, the researchers administered cannabinoids such as tetrahydrocannabinol (THC), a constituent derived from the cannabis plant, to the experimental animals. They findings showed that the THC significantly decreased the allergic reaction in comparison to untreated mice.

In order to better understand the molecular mechanism that may contribute to the increased CHS in cannabinoid-receptor deficient mice, the researchers performed a series of experiments which showed that mouse skin cells produce a specific chemical (a chemokine) which is involved in the annoying disease reaction. Activation of the endocannabinoid system in the skin upon exposure to a contact allergen lowers the allergic responses through modulating the production of this chemokine.

The results thus clearly show a protective role for the endocannabinoid system in contact allergy in the skin and suggest that development of cannabinoid compounds based on elements produced from the cannabis plant could enhance therapeutic treatment for humans.


'/>"/>

Contact: Jerry Barach
jerryb@savion.huji.ac.il
The Hebrew University of Jerusalem
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Cannabis for pain
2. Cannabis to be tested to help patients with respiratory diseases
3. Cannabis exerts protective effect against cancer
4. Relief For British MS Patients: Cannabis-Based Oral Spray
5. Alcohol And Drug Abuse (Cannabis) Leading Causes For Road Traffic Accidents
6. Government May Downgrade Cannabis
7. UK public misled over downgrading cannabis: Govt
8. Can Cannabis Cause Madness?
9. Campaigners Say No To Cannabis Reclassification
10. No Increased Schizophrenia Risk With Use Of Cannabis
11. Tackling of Cannabis Addiction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)... , Brain perfusion applic...nterprise using the Ziostation® thin-client sy...if (PRWEB) January 8, 2009 -- Ziosoft®, Inc. ...software for medical imaging , today announced th...Food and Drug Administration (FDA) for its CT brai...
(Date:1/7/2009)... , SEATTLE, Jan. 8 Ce... announced today that they received $7.5 million p...trum Pharmaceuticals, Inc. to commercialize and de..., the Company received the initial $7.5 million pa...action. The Company may earn up to an additional ...
(Date:1/7/2009)... , BOSTON The drive toward containing health ca...reducing physician productivity, impairing quality...l Deaconess Medical Center physicians suggest in a..., Citing studies in behavioral economics and psyc...D, express the fear that assigning a monetary valu...
(Date:1/7/2009)... , SAN MARCOS, Calif., Jan, 7 Natural Alternative... leading formulator, manufacturer and marketer of ...d that effective December 31, 2008 its former Pres... , , NAI also announced it completed certain amen...k. Among other changes the amendments extend the ...
Breaking Medicine News(10 mins):Health News:Ziosoft Receives FDA Clearance for CT Brain Perfusion Application 2Health News:Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals 2Health News:Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals 3Health News:Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals 4Health News:Cost containment focus could have consequences for health care delivery 2Health News:Natural Alternatives International, Inc. Announces Change in Executive Officer and Loan Modification and Extension 2
...high cholesterol levels are more likely to develop.... Researchers studied the eating habits and choles...about five years. The children were examined by do...ol, and LDL, or bad cholesterol, measured periodic...
...e that male babies who grow slowly in their first ... results hold true regardless of the socioeconomic...w infant growth may be accompanied by hampered bra...oor growth in infancy lead to lifelong impairment ...
...solved the puzzle of why baby boys are so much big...ring pregnancy. Women carrying male embryos consum...re protein and have a higher intake of carbohydrat...cepted that on average newborn boys are heavier th...
... the frequency of hot flashes in menopausal women,...gh an independent researcher said the drug's effec...rmone replacement therapy for menopausal symptoms ...sleep problems will be looked at more closely beca...
Other Medicine News:
(Date:1/7/2009)...RNewswire/ -- Circassia Ltd, a specialty,biopharm...care, today,announced that following successful c...une(R) anti-allergy technology, the company has no...se II clinical trial in cat allergy. The,study, w...ents with confirmed,cat allergies, and all the pa...
(Date:1/6/2009)...e-USNewswire/ -- Sequella, Inc., a clinical-stage ...pidemic potential, announced today that SQ109, its...osis (TB), was the first drug approved for evaluat...o Dynport Vaccine Company LLC and Quintiles Transn...titute of Allergy and Infectious Diseases (NIAID),...
(Date:1/5/2009)...wire-FirstCall/ -- Micromet, Inc.,(Nasdaq: MITI...proprietary,antibodies for the treatment of cance... an outlook on key events anticipated for the year...pdate on its research and development,programs at... 2009: Update on several preclinical BiTE antibodi...
(Date:12/27/2008)...Newswire-FirstCall/ -- Warner Chilcott Limited (Na...sidiaries and Mayne Pharma International Pty. Ltd....led lawsuits against each of Mutual Pharmaceutical...nc. ("Mylan") and Impax Laboratories, Inc. ("Impax...Jersey for infringement of Mayne,s U.S. Patent No....
Breaking Medicine Technology:Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 3Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Micromet Key Events for 2009 2Micromet Key Events for 2009 3Micromet Key Events for 2009 4Micromet Key Events for 2009 5Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 2Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 3UNIFEM and Avon Announce Partnership to End Violence Against Women and Advance Womens Empowerment 3A Company Contribution Benefits UN Trust Fund 13478 1UNIFEM and Avon Announce Partnership to End Violence Against Women and Advance Womens Empowerment 3A Company Contribution Benefits UN Trust Fund 13478 2UNIFEM and Avon Announce Partnership to End Violence Against Women and Advance Womens Empowerment 3A Company Contribution Benefits UN Trust Fund 13478 3UNIFEM and Avon Announce Partnership to End Violence Against Women and Advance Womens Empowerment 3A Company Contribution Benefits UN Trust Fund 13478 4UNIFEM and Avon Announce Partnership to End Violence Against Women and Advance Womens Empowerment 3A Company Contribution Benefits UN Trust Fund 13478 5LA BioMed researcher says unexpected increase in cancer risk found 13475 1LA BioMed researcher says unexpected increase in cancer risk found 13475 2LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 1LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 2LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 3LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 4LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 5LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 6LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 7LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 8LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 9LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 10LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 11LeMaitre Vascular Reports Q4 2007 Revenue of 2411 1 Million a 27 25 Increase 13471 12Bristol Myers Squibb Announces Dividend 3710 1
...erland, April 25, 2007 - Basilea Pharmaceutica Ltd...s showing that,patients with severe chronic hand e...oin. In two previous randomized clinical,trials, a...severe,chronic hand eczema in patients refractory ...ated that patients responsive to initial,treatment...
....--(BUSINESS WIRE)--Apr 25, 2007 - OSI,Pharmaceuti...ults,published yesterday in the Journal of Clinica... to gemcitabine chemotherapy,significantly improve... to patients with advanced pancreatic cancer. Data... Institute of Canada (NCIC),formed the basis of b...
Other Medicine Technology:Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 2Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 3Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 4Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 5OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study,Published in the Journal of Clinical Oncology Showed Survival,Improvement in Patients with Pancreatic Cancer 2OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study,Published in the Journal of Clinical Oncology Showed Survival,Improvement in Patients with Pancreatic Cancer 3OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study,Published in the Journal of Clinical Oncology Showed Survival,Improvement in Patients with Pancreatic Cancer 4
STABIBAG Hydrophilic Acrylic Lens.
XL STABI Hydrophilic Acrylic Lens.
FZ60 : the 1st monobloc hard & soft IOL. Thanks to an exclusive and patented process : the selective polymerisation, IOLTECH designed the first single piece rigid & soft IOL : the FZ60. This technolo
XL OCTO Hydrophilic Acrylic Lens.
Medicine Products: